Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing

Li Zhang, Ngoc Tung Tran, Hairui Su, Rui Wang, Yuheng Lu, Haiping Tang, Sayura Aoyagi, Ailan Guo, Alireza Khodadadi‐Jamayran, Dewang Zhou, Kun Qian, Todd Hricik, Jocelyn Côté, Xiaosi Han, Wenping Zhou, Suparna Laha, Omar Abdel‐Wahab, Ross L. Levine, Glen Raffel, Yanyan Liu, Dongquan Chen, Haitao Li, Tim M. Townes, Hengbin Wang, Haiteng Deng, Y. George Zheng, Christina S. Leslie, Minkui Luo, Xinyang ZhaoeLife 2015 · DOI

TL;DR

This paper reveals a novel regulatory mechanism where the protein arginine methyltransferase PRMT1 methylates RBM15, marking it for degradation by the E3 ligase CNOT4. This PRMT1-driven RBM15 depletion disrupts RNA splicing of key genes, hindering megakaryocyte differentiation, and offers a potential therapeutic target for acute megakaryocytic leukemia.

What Problem Does This Paper Address?

Cell differentiation, the process by which cells become specialized, is a fundamental aspect of development. While many factors are known to regulate this, the precise molecular mechanisms controlling the abundance and function of RNA-binding proteins (RBPs) during differentiation remain an active area of research. RBM15, an RBP implicated in various developmental processes and linked to cancers like megakaryocytic leukemia, was known to be important but its regulatory pathways were unclear. This study aims to elucidate how RBM15's activity is controlled, particularly in the context of megakaryocyte (MK) differentiation, and how this control might be disrupted in leukemia.

Methods

The researchers employed a multi-pronged approach:

  • Proteomics: Bio-orthogonal profiling of protein methylation (BPPM) was used to identify RBM15 as a substrate of PRMT1.
  • Biochemistry & Molecular Biology: Western blotting, co-immunoprecipitation, and in vitro methylation assays were used to confirm PRMT1's methylation of RBM15 at a specific residue (R578). They also investigated the role of ubiquitylation in RBM15 degradation using proteasome inhibitors and nickel-NTA pull-downs.
  • Cell Biology: Experiments involved transfecting cell lines (HEK293T, MEG-01) with various constructs (RBM15 wild-type and mutants, PRMT1 isoforms, shRNAs) to study protein stability, ubiquitylation, and cellular differentiation. They also used primary human CD34+ cells for more physiologically relevant differentiation studies.
  • RNA Biology: RNA immunoprecipitation (RIP) followed by RT-PCR and RIP-sequencing (RIP-seq) were used to identify RBM15's binding targets on pre-mRNA. RNA-sequencing (RNA-seq) was employed to analyze global changes in gene expression and alternative splicing upon RBM15 manipulation.
  • Bioinformatics: Data analysis included gene ontology (GO) pathway analysis, differential exon usage analysis (using DEXSeq and MISO programs), and survival analysis of AML patient data.

Datasets

  • Gene Expression Data: Data from AMKL patient samples was used to observe higher PRMT1 expression.
  • RNA-seq Data: Data from 200 AML samples (TCGA) was used for survival analysis.
  • RIP-seq Data: Newly generated RIP-seq data identified RBM15 binding sites on pre-mRNA.
  • RNA-seq Data: Newly generated RNA-seq data from RBM15 knockdown MEG-01 cells was used to analyze gene expression changes and alternative splicing.
  • Public Databases: HemaExplorer was used to examine PRMT1 and RBM15 expression in human hematopoietic lineages. Oncomine database was used to assess PRMT1 expression in various cancers.

Key Insights and Ideas

  • Methylation as a Degradation Signal: The discovery that PRMT1-mediated methylation of RBM15 at R578 directly triggers its ubiquitylation and subsequent degradation is a crucial insight. This highlights a post-translational modification-driven switch controlling protein abundance.
  • PRMT1 Isoform Specificity: The finding that PRMT1 V2 isoform is particularly effective at dimethylating RBM15 and influencing MK differentiation is significant, suggesting isoform-specific roles for PRMT1.
  • RBM15's Role in Alternative Splicing: RBM15 doesn't just bind RNA; it actively recruits splicing factors like SF3B1 to intronic regions, thereby controlling alternative splicing of key genes involved in MK differentiation. This reveals a direct link between RBP abundance and splicing regulation.
  • Therapeutic Potential: The identification of the PRMT1-RBM15 axis as a critical regulator in acute megakaryocytic leukemia opens up new avenues for therapeutic intervention by targeting PRMT1.

Key Results

  • PRMT1 methylates RBM15 at residue R578.
  • Methylation of RBM15 by PRMT1 leads to its degradation via ubiquitylation by the E3 ligase CNOT4.
  • Overexpression of PRMT1 in acute megakaryocytic leukemia cell lines blocks megakaryocyte terminal differentiation by reducing RBM15 protein levels.
  • RBM15 binds to pre-mRNA intronic regions of genes critical for megakaryopoiesis (e.g., GATA1, RUNX1, TAL1, c-MPL).
  • RBM15 binding to intronic regions recruits the splicing factor SF3B1, influencing alternative splicing.
  • Knockdown of RBM15 leads to altered ratios of GATA1 isoforms (favoring GATA1s) and c-MPL isoforms (favoring c-MPL-exon9-), impacting MK differentiation.
  • PRMT1 inhibition (using DB75) in CD34+ cells promotes MK differentiation, suggesting a role for PRMT1 in suppressing maturation.

Limitations and Future Work

  • PRMT1 Isoform Specificity: While PRMT1 V2 appears more relevant for MK maturation, the precise roles of PRMT1 V1 and V2 in other contexts and their specific substrate preferences require further investigation.
  • CNOT4 Interaction Domain: The exact domain(s) on CNOT4 that interact with methylated RBM15 are not fully elucidated, though peptide pull-down experiments suggest the methylated region of RBM15 is sufficient for binding.
  • Other Methylation Sites: Low levels of RBM15 methylation persist even with the R578K mutation, suggesting other arginines might be methylated by PRMT1 or other PRMTs. However, these other sites do not appear to be involved in methylation-mediated ubiquitylation.
  • Fusion Protein Methylation: It remains to be determined if the RBM15-MKL1 fusion protein, found in AMKL, is methylated by PRMT1.
  • Therapeutic Development: The authors suggest that developing V2-specific PRMT1 inhibitors could be a more targeted therapeutic approach, given the isoform's role in oncogenesis.
  • Broader Biological Roles: While the study focuses on MK differentiation, the ubiquitous expression of PRMT1 and RBM15 suggests their pathway may regulate cell fate decisions in other tissues as well. Further research into these broader roles is warranted.

Summary updated

Abstract

RBM15, an RNA binding protein, determines cell-fate specification of many tissues including blood. We demonstrate that RBM15 is methylated by protein arginine methyltransferase 1 (PRMT1) at residue R578, leading to its degradation via ubiquitylation by an E3 ligase (CNOT4). Overexpression of PRMT1 in acute megakaryocytic leukemia cell lines blocks megakaryocyte terminal differentiation by downregulation of RBM15 protein level. Restoring RBM15 protein level rescues megakaryocyte terminal differentiation blocked by PRMT1 overexpression. At the molecular level, RBM15 binds to pre-messenger RNA intronic regions of genes important for megakaryopoiesis such as GATA1, RUNX1, TAL1 and c-MPL. Furthermore, preferential binding of RBM15 to specific intronic regions recruits the splicing factor SF3B1 to the same sites for alternative splicing. Therefore, PRMT1 regulates alternative RNA splicing via reducing RBM15 protein concentration. Targeting PRMT1 may be a curative therapy to restore megakaryocyte differentiation for acute megakaryocytic leukemia.
BibTeX
@inproceedings{zhang2015cross,
  author = {Li Zhang and Ngoc Tung Tran and Hairui Su and Rui Wang and Yuheng Lu and Haiping Tang and Sayura Aoyagi and Ailan Guo and Alireza Khodadadi‐Jamayran and Dewang Zhou and Kun Qian and Todd Hricik and Jocelyn Côté and Xiaosi Han and Wenping Zhou and Suparna Laha and Omar Abdel‐Wahab and Ross L. Levine and Glen Raffel and Yanyan Liu and Dongquan Chen and Haitao Li and Tim M. Townes and Hengbin Wang and Haiteng Deng and Y. George Zheng and Christina S. Leslie and Minkui Luo and Xinyang Zhao},
  title = {{Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing}},
  booktitle = {eLife},
  year = {2015},
  doi = {10.7554/elife.07938},
}
Figure